Is WEIGHT DECREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed WEIGHT DECREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 67 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported WEIGHT DECREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and WEIGHT DECREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause WEIGHT DECREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes WEIGHT DECREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if WEIGHT DECREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing WEIGHT DECREASED: 67
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where WEIGHT DECREASED is a reported side effect: 2.0126%

FDA reports of any drug causing WEIGHT DECREASED : 73934
Average percentage for all medicated patients where WEIGHT DECREASED is reported as a complication: 0.4634%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with WEIGHT DECREASED:

BYETTA (15971 patients)
ASPIRIN (5688 patients)
METFORMIN HCL (4766 patients)
FOSAMAX (4717 patients)
LIPITOR (3421 patients)
HUMIRA (3095 patients)
NEXIUM (3052 patients)
ZOMETA (2789 patients)
LANTUS (2788 patients)
PREDNISONE (2769 patients)
SEROQUEL (2753 patients)
LISINOPRIL (2712 patients)
SYNTHROID (2605 patients)
FORTEO (2604 patients)
GLUCOPHAGE (2413 patients)
ACCUTANE (2409 patients)
VIOXX (2294 patients)
LASIX (2252 patients)
XANAX (2119 patients)
AVONEX (2045 patients)
ACTOS (1972 patients)
SANDOSTATIN LAR (1968 patients)
ZOLOFT (1945 patients)
REMICADE (1934 patients)
OMEPRAZOLE (1932 patients)
ATENOLOL (1893 patients)
NEURONTIN (1888 patients)
COUMADIN (1874 patients)
PRILOSEC (1866 patients)
SIMVASTATIN (1843 patients)
AREDIA (1780 patients)
LYRICA (1752 patients)
METHOTREXATE (1745 patients)
FOLIC ACID (1744 patients)
FUROSEMIDE (1723 patients)
CHANTIX (1696 patients)
PLAVIX (1695 patients)
AVANDIA (1669 patients)
DURAGESIC-100 (1639 patients)
HYDROCHLOROTHIAZIDE (1632 patients)
RIBAVIRIN (1617 patients)
PROTONIX (1617 patients)
DIGOXIN (1611 patients)
AMBIEN (1590 patients)
ZOCOR (1567 patients)
OXYCONTIN (1560 patients)
CYMBALTA (1550 patients)
CELEBREX (1521 patients)
METFORMIN (1503 patients)
LEVOTHYROXINE SODIUM (1480 patients)
NORVASC (1470 patients)
VITAMIN D (1464 patients)
AMARYL (1456 patients)
TOPROL-XL (1442 patients)
GLIPIZIDE (1414 patients)
PREVACID (1412 patients)
LEXAPRO (1367 patients)
GLYBURIDE (1362 patients)
PEGASYS (1344 patients)
ATIVAN (1330 patients)
CRESTOR (1315 patients)
ACETAMINOPHEN (1292 patients)
ENBREL (1292 patients)
ALBUTEROL (1276 patients)
PERCOCET (1234 patients)
HUMALOG (1230 patients)
PAXIL (1224 patients)
VICODIN (1223 patients)
POTASSIUM CHLORIDE (1205 patients)
PEG-INTRON (1194 patients)
TYSABRI (1178 patients)
PREDNISONE TAB (1165 patients)
TOPAMAX (1153 patients)
CALCIUM (1123 patients)
IBUPROFEN (1113 patients)
LEVAQUIN (1109 patients)
LORAZEPAM (1106 patients)
DIOVAN (1085 patients)
ALLOPURINOL (1070 patients)
PROZAC (1053 patients)
KLONOPIN (1037 patients)
VICTOZA (1030 patients)
ZYPREXA (1006 patients)
CLONAZEPAM (996 patients)
ZOFRAN (972 patients)
INSULIN (968 patients)
OXYCODONE HCL (954 patients)
MULTI-VITAMINS (951 patients)
DEXAMETHASONE (946 patients)
ADVAIR DISKUS 100/50 (945 patients)
EFFEXOR (933 patients)
GABAPENTIN (930 patients)
WELLBUTRIN (928 patients)
WARFARIN SODIUM (912 patients)
DECADRON (909 patients)
NEXAVAR (898 patients)
PREMARIN (894 patients)
METOPROLOL TARTRATE (894 patients)
VALIUM (890 patients)
MORPHINE (869 patients)
AMOXICILLIN (867 patients)
DIAZEPAM (851 patients)
AMLODIPINE (845 patients)
COREG (836 patients)
ALPRAZOLAM (828 patients)
ZANTAC (820 patients)
LORTAB (796 patients)
REBIF (784 patients)
TRAZODONE HCL (779 patients)
PREDNISOLONE (737 patients)
REVLIMID (734 patients)
MULTI-VITAMIN (734 patients)
RISPERDAL (732 patients)
VITAMIN B-12 (728 patients)
VITAMIN E (717 patients)
SINGULAIR (712 patients)
SPIRIVA (704 patients)
HEPARIN SODIUM INJECTION (700 patients)
COPEGUS (696 patients)
COZAAR (686 patients)
NOVOLOG (679 patients)
FENTANYL (673 patients)
REGLAN (662 patients)
CELEXA (660 patients)
TRAMADOL HCL (654 patients)
NITROGLYCERIN (651 patients)
ZETIA (647 patients)
STRATTERA (644 patients)
ALTACE (642 patients)
FLEXERIL (642 patients)
METOPROLOL (627 patients)
FISH OIL (619 patients)
GLIMEPIRIDE (613 patients)
CISPLATIN (613 patients)
EFFEXOR XR (611 patients)
TRICOR (608 patients)
LEVOXYL (604 patients)
SPIRONOLACTONE (602 patients)
ARIMIDEX (593 patients)
COMPAZINE (591 patients)
ACTONEL (589 patients)
RANITIDINE (585 patients)
EXJADE (583 patients)
BETASERON (580 patients)
ZYRTEC (577 patients)
REBETOL (575 patients)
MORPHINE SULFATE (573 patients)
DEPAKOTE (570 patients)
AMITRIPTYLINE HCL (569 patients)
BACTRIM (568 patients)
CLOZARIL (566 patients)
LOPRESSOR (563 patients)
ARANESP (558 patients)
CIPROFLOXACIN (557 patients)
CALCIUM CARBONATE (553 patients)
VYTORIN (551 patients)
FLUOROURACIL (550 patients)
XELODA (549 patients)
ASCORBIC ACID (546 patients)
SUTENT (546 patients)
TYLENOL (535 patients)
CLONIDINE (531 patients)
CYCLOPHOSPHAMIDE (530 patients)
PROMETHAZINE (529 patients)
RADIATION THERAPY (526 patients)
FLOMAX (525 patients)
BENADRYL (513 patients)
DILAUDID (511 patients)
ZITHROMAX (507 patients)
TYLENOL (CAPLET) (504 patients)
GLEEVEC (503 patients)
PANTOPRAZOLE (502 patients)
LAMICTAL (499 patients)
JANUVIA (497 patients)
LOVENOX (496 patients)
HUMULIN N (496 patients)
ACIPHEX (495 patients)
COLACE (495 patients)
PEPCID (494 patients)
METOPROLOL SUCCINATE (491 patients)
ENALAPRIL MALEATE (491 patients)
TAXOTERE (490 patients)
CHEMOTHERAPEUTICS NOS (489 patients)
POTASSIUM (487 patients)
AVASTIN (483 patients)
AUGMENTIN '125' (476 patients)
ULTRAM (472 patients)
HYDROCODONE (472 patients)
RAMIPRIL (471 patients)
CARBOPLATIN (469 patients)
SOMA (468 patients)
GLUCOTROL (467 patients)
REMERON (467 patients)
MS CONTIN (467 patients)
LANSOPRAZOLE (466 patients)
GLUCOVANCE (462 patients)
ALLEGRA (459 patients)
FLONASE (459 patients)
ABILIFY (458 patients)
IRON (456 patients)
CIPRO (454 patients)
FLAGYL (453 patients)
PROCRIT (448 patients)
ELAVIL (439 patients)
KEPPRA (438 patients)
THALIDOMIDE (437 patients)
FERROUS SULFATE TAB (437 patients)
TEGRETOL (435 patients)
TEMAZEPAM (432 patients)
BACLOFEN (432 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about WEIGHT DECREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.